Infliximab injectable solution is available as brand-name drugs. It’s not available in a generic version. Brand names: Remicade, Inflectra, Renflexis. Infliximab comes in an injectable solution for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After previously discontinuing infliximab, 35% of ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

HealthDay News — Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), according to a living clinical practice guideline issued by ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Learn everything you need to know about Infliximab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

Please provide your email address to receive an email when new articles are posted on . Week-22 remission rates were 81% among patients using infliximab and 56% in those on cyclophosphamide. Mild to ...

Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease (see section 1.6) whose disease has not responded to ...